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Background: Scanning for mutations in BRCA1 and
BRCA2 in a large number of samples is hampered by the
large sizes of these genes and the scattering of mutations
throughout their coding sequences. Automated capillary
electrophoresis has been shown to be a powerful system
to detect mutations by either single-strand conformation
polymorphism or heteroduplex analysis (HA).
Methods: We investigated the adaptation of gel-based
HA of BRCA1 and BRCA2 to a fluorescent multicapil-
lary platform to increase the throughput of this tech-
nique. We combined multiplex PCR, three different
fluorescent labels, and HA in a 16-capillary DNA se-
quencer and tested 57 DNA sequence variants (11 inser-
tions/deletions and 46 single-nucleotide changes) of
BRCA1 and BRCA2.
Results: We detected all 57 DNA changes in a blinded
assay, and 2 additional single-nucleotide substitutions
(1186 A>G of BRCA1 and 3624 A>G of BRCA2), previ-
ously unresolved by conformation-sensitive gel electro-
phoresis. Furthermore, different DNA changes in the
same PCR fragment could be distinguished by their
peak patterns.
Conclusions: Capillary-based HA is a fast, efficient, and
sensitive method that considerably reduces the amount
of “hands-on” time for each sample. By this approach,
the entire coding regions of BRCA1 and BRCA2 from
two breast cancer patients can be scanned in a single run
of 90 min.
© 2004 American Association for Clinical Chemistry
Mutations in BRCA1 (MIM 113705) and BRCA2 (MIM
600185) account for 20% of families with evidence of
inherited susceptibility to breast cancer (1 ). The BRCA1
gene is distributed in 24 exons with 5589 nucleotides of
coding sequence, which produce a protein of 1863 amino
acids (2 ). The BRCA2 gene is composed of 27 exons and
encodes an 11 385-bp transcript that codes for a protein of
3418 amino acids (3 ).
Genetic testing of BRCA1 and BRCA2 allows identifi-
cation of mutation carriers who may benefit from tailored
screening and prevention protocols. To date, 2600 dis-
tinct DNA sequence variants have been described
throughout the sequences of BRCA1 and BRCA2 in the
BIC database (4 ). The search for mutations therefore
requires extensive analysis of the entire coding sequence
of both genes.
Numerous techniques have been developed for the
detection of subtle DNA sequence changes, including
single-strand conformation polymorphism analysis (5 ),
denaturing gradient gel electrophoresis (6 ), denaturing
HPLC (7 ), and heteroduplex analysis (HA)1 (8 ). All of
these techniques have limitations, and many are not
suitable for high-throughput strategies, e.g., denaturing
gradient gel electrophoresis. HA by conformation-sensi-
tive gel electrophoresis (CSGE) (8 ) is considered to detect
almost 100% of sequence variants and is suitable for
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mutation scanning of many disease-causing genes, in-
cluding BRCA1 and BRCA2 (9–12). Using this method we
have detected 87 different DNA changes in BRCA1 and
BRCA2 in300 samples from breast cancer patients [Refs.
(12, 13) and Infante et al., manuscript in preparation].
However, standard slab gel CSGE is time-consuming and
labor-intensive.
The introduction of fluorescent labels as well as gel-
based laser detection electrophoresis platforms dramati-
cally improved the throughput of CSGE (14–16), but
these types of sequencers are still labor-intensive. Capil-
lary systems substantially reduce the amount of “hands-
on” time required to process each sample because long
and laborious steps, such as gel preparation and sample
loading, are omitted. Several reports have shown that it is
possible to transfer fluorescent HA from a gel-based
system to a monocapillary system (17–19). These reports
demonstrated that capillary HA is fast, sensitive, and
reproducible.
With a view to designing a high-throughput method,
we adapted our gel-based HA of BRCA1 and BRCA2 to a
fluorescent multicapillary system. We tested the ability of
this method to detect 57 DNA changes, 11 insertions/
deletions and 46 single-nucleotide substitutions (SNS; 25
in BRCA1 and 32 in BRCA2), previously detected by
standard CSGE.
Materials and Methods
dna isolation and samples
DNA from breast cancer patients and controls was ex-
tracted from EDTA-anticoagulated blood samples by
standard protocols. The 57 DNA changes investigated
comprised 46 SNS and 11 small insertions or deletions,
including 10 frameshift mutations and 1 intronic insertion
(Tables 1 and 2). Mutation nomenclature was basically
according to den Dunnen and Antonarakis (20 ).
multiplex pcr
Exons 2–24 of BRCA1 and 2–27 of BRCA2 were amplified
in 72 PCR fragments [30 for BRCA1 and 42 for BRCA2;
primer sequences were kindly provided by M. Stratton
(Institute of Cancer Research, Sutton, Surrey, UK), and are
shown in Tables 3 and 4 of the Data Supplement that
accompanies the online version of this article at http://
www.clinchem.org/content/vol50/issue2/]. Some primer
pairs were newly designed (Tables 3 and 4 in the online
Data Supplement). Fragments ranged in size from 179 to
584 bp (BRCA1) and from 194 to 575 bp (BRCA2). Large
exons, such as BRCA1 exon 11 and BRCA2 exons 10, 11,
14, and 27, were amplified in several overlapping frag-
ments.
These fragments were divided into 23 multiplex-PCR
groups in relation to their sizes and compatible amplifi-
cation conditions (Tables 3 and 4 in the online Data
Supplement). One primer of each pair was labeled with
6-carboxyfluorescein (FAM), hexachloro-6-carboxyfluo-
rescein (HEX), or 2,7,8-benzo-5-fluoro-2,4,7-trichloro-5-
carboxyfluorescein (NED; Dye Set D; Applied Biosys-
tems). Multiplex PCRs for large fragments were carefully
set up to ensure optimum amplification of these frag-
ments and to obtain peak values similar to those for other,
smaller fragments in the same reaction. As a general rule
in each multiplex group, larger fragments required higher
concentrations of primers.
PCRs were carried out in a final volume of 25 L
containing 200 ng of genomic DNA; primers at the con-
centrations specified in Tables 3 and 4 of the online Data
Supplement; 600 M each deoxynucleotide triphosphate;
AmpliTaq Gold 1 buffer (Applied Biosystems) or Opti-
prime Buffer #6 (Stratagene), as indicated in Tables 3 and
4 of the online Data Supplement; MgCl2 at 2.0–2.5 mM
when using AmpliTaq Gold buffer; and 1 U of AmpliTaq
Gold or 2.5 U of AmpliTaq DNA polymerase (Applied
Biosystems).
BRCA1 exon 7 could not be included in this analysis
because three very frequent insertion/deletion polymor-
phisms [6–7 copies of the trinucleotide CTT and 1 or 2
copies of C(T10–12)] are located 17 and 40 bp downstream
of the 3 end of exon 7. Consequently, most samples show
Table 1. BRCA1 DNA changes analyzed by
capillary electrophoresis.
DNA changea
(amino acid change)
Type of
change
(effect)
Exon
(fragment)
BIC number
(4) or Ref.
IVS1-115 TC SNS (UV)b 2 Velasco et al. (13)
IVS2-14 CT SNS (P) 3 2637
233 GA SNS (P) 3 1317
330 A>G SNS (Sp) 5 1944
IVS5  1 G>A SNS (Sp) I-5 2843
655 AG (Y179C) SNS (M) 8 1690
IVS8-58delT D (P) I-8 1322
710 CT SNS (P) 9 1237
1135insA I (Fr) 11 (a2) 1008
2201CT SNS (P) 11 (e1) 1047
2731 CT (P871L) SNS (M) 11 (c) 1067
3232 AG (E1038G) SNS (M) 11 (d1) 1087
3667 AG (K1183R) SNS (M) 11 (d2) 1099
3958delCTCAG;insAGGC D-I (N) 11 (g) 4365
IVS11  15 T>C SNS (UV) 11 (g) Velasco et al. (13)
4427 TC SNS (P) 13 1128
IVS13-10 CT SNS (P) 14 2419
IVS14-63 CG SNS (P) 15 4234
4654 GT (S1512I) SNS (M) 15 1136
4956 A>G (S1613G) SNS (M) 16 1140
5236 GA (G1706E) SNS (M) 18 3393
5242 CA (A1708E) SNS (M) 18 1147
IVS18-1 G>A SNS (Sp) 19 3942
IVS20  1 G>A SNS (Sp) 20 2100
IVS19-2 A>G SNS (Sp) 20 3400
a Mutations studied to establish optimal HA conditions are shown in bold.
Disease-causing mutations are shown in italics. Amino acid changes are shown
only for missense and nonsense mutations.
b UV, unclassified variant; P, polymorphism; Sp, splicing; M, missense; D,
deletion; I, insertion; Fr, frameshift; N, nonsense.
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band shifts in HA that mask the finding of other exon 7
DNA changes. The proximity of one of these polymor-
phisms to the exon 7–intron 7 boundary (only 17 bp)
forces the design of a reverse primer spanning the 5
splice site of intron 7; mutations affecting it would there-
fore be missed. We thus searched for mutations in exon 7
by direct sequencing.
thermocycling conditions
Two different sets of thermocycling conditions were per-
formed in a GeneAmp PCR System 9700 (Applied Biosys-
tems; see Tables 3 and 4 in the online Data Supplement):
For BRCA1 groups, thermocycling included 35 cycles of
94 °C for 1 min, 56 °C for 1 min, and 72 °C for 2 min. For
BRCA2 groups, thermocycling included the following
touchdown protocol (16 ): 35 cycles of 94 °C for 45 s, and
touchdown annealing temperatures from 60 to 50 °C for
45 s and 72 °C for 60 s. However, to avoid nonspecific
bands from old DNA samples, we also amplified the
groups 2D, 2F, 2I, and 2K with the following conditions:
35 cycles of 94 °C for 45 s, 52 °C for 45 s, and 72 °C for 60 s.
An initial denaturation step at 95 °C for 2 min (10 min
when using AmpliTaq Gold) and a final extension step at
72 °C for 5 min were added to all thermocycling protocols.
ha
A heteroduplex formation step was performed in the
same PCR instrument and consisted of heating the PCR
products to 98 °C for 5 min and allowing them to cool to
25 °C in six steps: cooling to 90 °C over 5 min, cooling to
80 °C over 5 min, cooling to 75 °C over 10 min, cooling
to 60 °C over 10 min, cooling to 40 °C over 20 min, and
cooling to 25 °C over 20 min.
HA by manual CSGE was performed according to
previously reported protocols (8 ).
Fluorescent HA was carried out under nondenaturing
conditions as follows. PCR products labeled with FAM,
HEX, and NED were pooled together and diluted 1:5–1:20
in deionized water with 0.5 L of Genescan 500-ROX or
Genescan 2500-ROX size calibrators (Applied Biosys-
tems). These size calibrators were used to compensate for
any inter- and intracapillary variations in electrophoretic
migration.
All PCR products were resolved on an ABI 3100 DNA
sequencer (16 capillaries; Applied Biosystems). This in-
strument has a capacity of two plates of 96 or 384 samples,
which are injected automatically during the run. The
matrix concentration was varied between 3% and 5%
Genescan polymer (Applied Biosystems) according to a
previous report (17 ), with 0–100 mL/L glycerol, and 1
Tris-borate-EDTA (TBE) or 1 electrophoresis buffer with
EDTA (Applied Biosystems). Denaturing agents, such as
formamide or urea, were omitted because they reduce the
lifespan of the capillary and do not significantly improve
the resolution of heteroduplexes (17 ). The capillary arrays
were 36 and 50 cm long (Applied Biosystems). Run
temperatures (20–35 °C), run voltages (5, 7.5, 10, 12.5, and
15 kV), sample injection voltages and times, and run times
(1.5 h) were selected in the Data Collection Software, Ver.
1.1 (Applied Biosystems).
Fragment analysis was carried out blinded by use of
Genescan software, Ver. 3.7 (Applied Biosystems). Het-
eroduplexes were identified by the presence of altered
peak patterns compared with a control sample.
sequencing
Fragments showing an altered pattern were sequenced
with the BigDye® Terminator Sequencing Kit, Ver. 3.1
(Applied Biosystems), with unlabeled forward and re-
verse primers.
Table 2. BRCA2 DNA changes analyzed by
capillary electrophoresis.
DNA changea
(amino acid change)
Type of
change
(effect)
Exon
(fragment)
BIC number
(4) or Ref.
203 GA SNS (P)b 2 1666
IVS6-19 CT SNS (P) 7 2164
IVS8  56 CT SNS (P) 8 2411
1538delAAGA D (Fr) 10 (BD1) 2885
1342 CA (H372N) SNS (M) 10 (BD1) 1668
1593 AG SNS (P) 10 (BD1) 1106
3036delACAA D (Fr) 11 (EF) 1021
3199 GA (N991D) SNS (M) 11 (EF) 1903
3492insT I (Fr) 11 (GH) 2067
3690 CT SNS (UV) 11 (GH) Velasco et al. (13)
4150 GT (E1308X) SNS (N) 11 (IL2) 2480
4486 G>T (D1420Y) SNS (M) 11 (MO) 1273
4898 CG (T1557S) SNS (M) 11 (PQ) 4874
5374delTATG D (Fr) 11 (R) Duran et al. (12)
5972 C>T (T1915M) SNS (M) 11 (UV) 1108
6126delT D (Fr) 11 (UV) Duran et al. (12)
6503delTT D (Fr) 11 (WX) 1047
6518 C>T (T2097M) SNS (M) 11 (WX) 2297
6884 C>G (S2219X) SNS (N) 11 (YZ) 1054
7288 CT (Q2354X) SNS (N) 14 (A) Duran et al. (12)
7365 AG SNS (UV) 14 (A) Velasco et al. (13)
7470 AG SNS (P) 14 (B) 1125
IVS14  53 CT SNS (P) 14 (B) 2738
IVS16-14 TC SNS (P) I-16 1126
9078 GT (K2950N) SNS (M) 22 1405
9254delATCAT D (Fr) 23 1073
9266 CT (T3013I) SNS (M) 23 1415
9476 AT (K3083X) SNS (N) 24 Duran et al. (12)
9520 TC (Y3098H) SNS (M) 25 1078
9538delAA D (Fr) 25 1422
10204 AT (K3326X) SNS (N-P) 27 (B) 1179
10462 AG (I3412V) SNS (M) 27 (B) 1452
a Mutations studied to establish optimal HA conditions are shown in bold.
Disease-causing mutations are shown in italics. Amino acid changes are shown
only for missense and nonsense mutations.
b P, polymorphism; D, deletion; Fr, frameshift; M, missense; I, insertion; UV,
unclassified variant; N, nonsense.
Clinical Chemistry 50, No. 2, 2004 315
Results
optimization of electrophoretic conditions
To determine the best resolution settings, we evaluated
different run conditions with use of 15 randomly selected
DNA sequence variants (11 SNS and 4 insertions/dele-
tions). These mutations are shown in bold font in Tables 1
and 2. Multiplex PCRs were performed as described in the
Materials and Methods.
We assessed capillary length (36 and 50 cm), run
voltage, run temperature, different concentrations of Ge-
nescan polymer (3–5%) and glycerol (0–100 mL/L), and
two electrophoresis buffers, 1 TBE and 1 ABI, both
with 0–100 mL/L glycerol.
A polymer concentration of 5% and the presence of
glycerol (100 mL/L) improved the resolution of all DNA
changes. In addition, intermediate run voltages (10–12.5
kV) and low temperatures (20–25 °C) favored the detec-
tion of the DNA variants. However, with regard to the
resolution of heteroduplexes, no clear differences were
observed when we used run voltages of 10–12.5 kV and
temperatures of 20–25 °C. Nevertheless, visualization of
the otherwise poorly resolved heteroduplexes showed
certain benefits at 10 kV and 20 °C (data not shown). The
50-cm capillary array, which was in principle suitable just
for sequencing, gave much better resolution of peak shifts
than the 36-cm array, which did not distinguish wild-type
from mutant samples for several SNS.
The final, optimum electrophoretic conditions were as
follows: 5% Genescan polymer in 1 TBE buffer with 100
mL/L glycerol, 1 TBE with 100 mL/L glycerol as
electrophoresis buffer, a 50-cm capillary array, 10 kV, and
20 °C for 90 min. Under these conditions, anomalous
patterns for all 15 DNA variants were detected. Any
changes in these conditions led to poor resolution of
heteroduplexes or no detection of the mutations. For
example, the choice of other electrophoresis buffers, such
as 1 ABI with or without glycerol or 1 TBE without
glycerol, prevented the detection of at least 1 of these 15
DNA changes. The dramatic effects of the electrophoresis
buffer and glycerol on peak patterns are illustrated in Fig.
1. The mutation IVS20  1 GA at exon 20 of BRCA1
clearly showed four different peak patterns, which went
from a pattern showing two overlapping peaks (1 ABI
buffer100 mL/L glycerol; Fig. 1B) to the best resolution,
with a pattern of four peaks (1 TBE  100 mL/L
glycerol; Fig. 1D) corresponding to the two homoduplexes
and the two heteroduplexes.
identification of altered peak patterns in 59
dna changes
We had previously identified 87 different DNA changes
by CSGE (data not shown). To compare the sensitivity of
standard CSGE with that of HA in a fluorescent multi-
capillary system, we evaluated 57 BRCA mutants (25 in
BRCA1 and 32 in BRCA2), including the 15 previously
analyzed mutations. Because single-base changes are the
most commonly occurring mutations in genetic diseases,
the sensitivity of any mutational scanning technique is
determined by its ability to detect these types of changes.
For this reason, we studied 46 SNS, of which 18 were
Fig. 1. Mutation IVS20  1 GA of BRCA1 FAM-exon 20 assayed with different buffer compositions.
(A), 1 ABI buffer; (B), 1 ABI buffer  100 mL/L glycerol; (C), 1 TBE; (D), 1 TBE  100 mL/L glycerol. The four experiments were performed under the following
fixed conditions: 5% Genescan polymer with either 1 ABI or 1 TBE buffer and with or without 100 mL/L glycerol; 50-cm capillary length; 10 kV at 20 °C for 90 min.
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intronic or exonic variants, 18 were missense, 5 were
nonsense, and 5 were splicing mutations. The remaining
11 alterations were small insertions or deletions (1 in-
tronic and 10 frameshift mutations).
All of the samples carrying these DNA changes, as well
as the control samples, were processed as described in the
Material and Methods. All of the insertions/deletions
showed a clearly altered peak pattern, which in general
contained the four expected bands corresponding to the
two homoduplexes and the two heteroduplexes (Fig. 2A).
The altered peak patterns of SNS were quite variable
and complex. Basically, four different patterns could be
distinguished: one abnormal peak (Fig. 2B), two peaks
(Fig. 2C), three peaks (Fig. 2D), and four peaks that
corresponded to the two homoduplexes and the two
heteroduplexes (Fig. 2E). The most difficult pattern to
identify was the first one (one abnormal peak), but it was
also the least common type. Other patterns with two,
three, or four overlapping peaks could also be identified.
All 57 DNA variants were detected under the condi-
tions described above. Moreover, peak shifts correspond-
ing to two additional single-nucleotide changes, which we
had not detected previously by CSGE, were also visual-
ized when we tested multiplex groups of one patient
carrying IVS20 1GA (group 1A in Table 3 of the online
Data Supplement) and one control sample (group 2J in
Table 4 of the online Data Supplement). These mutations
were as follows: 1186 AG (BRCA1 exon 11a2; BIC no.
1014) and 3624 AG (BRCA2 exon 11GH; BIC no. 1661).
Both were in large fragments of 453 and 566 bp, respec-
tively. Remarkably, 12 of 59 mutations (20%) detected by
capillary HA were located within fragments 500 bp,
considered as the upper limit for CSGE, and all of them
were successfully identified (data not shown).
specificity of capillary ha
To establish the specificity of the capillary HA method,
we compared patterns from different mutations in the
Fig. 2. Peak patterns of insertions/deletions and SNS.
(A), frameshift mutation 1538delAAGA from exon fragment FAM-10BD1 of BRCA2; (B), 3199GA from exon fragment FAM-11EF of BRCA2; (C), 3667 AG from exon
fragment NED-11d2 of BRCA1; (D), 7288 CT from HEX-exon 14-A of BRCA2; (E), IVS5  1 GA from FAM-exon 5 of BRCA1.
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same PCR fragment (see Tables 1 and 2) under the
optimum settings. All of the mutations in each amplicon
could be distinguished by their patterns. Shown in Fig. 3A
are the patterns for the mutations 3690 CT, 3624 AG,
and 3492insT from BRCA2 exon fragment 11GH. In addi-
tion, wild-type homozygous samples could be differenti-
ated from mutant homozygous samples for some frequent
polymorphisms, such as 3667 AG (K1183R) of BRCA1
exon fragment 11d2, which was identified in 30% of
samples and has been classified as a missense polymor-
phism (BIC database) (4 ). Shown in Fig. 3B are the three
expected patterns for mutation K1183R: homozygous
wild type (wt/wt), heterozygous wt/K1183R, and ho-
mozygous K1183R/K1183R.
Discussion
The purpose of this study was to develop a sufficiently
sensitive, high-throughput method to scan the entire
coding sequences of BRCA1 and BRCA2 with a view to
offering rapid and reliable genetic analysis to breast and
ovarian cancer patients. This new method may be of
interest for genetic testing laboratories that routinely
screen BRCA1 and BRCA2 in a large number of samples.
Preliminary studies had demonstrated increased
throughput of HA and single-strand conformation poly-
morphism analysis by the inclusion of fluorescent labels
and gel electrophoresis in automated sequencers (14–16).
Additional progress in throughput was achieved when
electrophoresis was transferred to capillary systems
(17, 21). It was suggested that further advances in
throughput could be achieved by use of multicapillary
systems and different labels.
We report here substantial improvement in the HA of
BRCA1 and BRCA2 by use of fluorescent 16-capillary
platforms that provide a faster, high-throughput, repro-
ducible, and more sensitive method. The increase in the
throughput of our method relies on four features: (a) use
of a 16-capillary system, which reduces to a large extent
the time needed to process each sample; (b) multiplex
PCR, which allows a decrease in the number of PCR
reactions/sample [BRCA1 and BRCA2 can be amplified in
72 PCR fragments divided into only 23 multiplex PCR
Fig. 3. Electropherograms showing the specificity of capillary HA.
(A), peak patterns of three different mutations at the same exon fragment (FAM-ex11GH of BRCA2); (B), differentiation of homozygous wild-type (wt/wt) samples (top
panel), heterozygous samples for mutation 3667 AG (wt/K1183R; middle panel), and homozygous mutant samples (K1183R/K1183R; bottom panel).
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groups (see Tables 3 and 4 in the online Data Supple-
ment)]; (c) use of different labels for each multiplex PCR
group (FAM, HEX, and NED), which allows the mixture
of three differently labeled multiplex-PCR fragments in
one tube; and (d) use of a single assay per sample. In
contrast, in other capillary-based mutation detection tech-
niques, different sets of conditions have been suggested to
ensure detection of all mutations (19, 22). This would
considerably increase the amount of data to be analyzed,
specially when a large number of samples are to be
screened.
Thus, 8–10 PCR fragments can be analyzed in one
capillary per run, meaning that analysis of the entire
coding regions of BRCA1 and BRCA2 from two patients
can be performed in a single run of 1.5 h.
Using this method, we have detected all 57 tested
mutations. Given that more than 60% of the pathogenic
mutations reported in the BIC database are frameshifts
(4 ), it should be pointed out that all insertions/deletions
were easily detected by virtue of their peak patterns (Fig.
2A). However, one of the main aims of this study was to
confirm the feasibility and sensitivity of our method for
the detection of SNS (46 of 57 DNA changes assayed were
SNS) because there is increasing evidence implicating
SNS in inherited breast cancer through alteration of either
the protein function (missense mutations) (23 ) or the
RNA splicing as a result of disruption of exonic splicing
enhancers (any exonic DNA change, including silent
mutations) (24 ). Remarkably, all of the SNS analyzed
were detected with high accuracy. Furthermore, the sen-
sitivity of heteroduplex detection was improved with
respect to standard CSGE; capillary HA identified two
other mutations (1186AG of BRCA1 exon 11a2 and 3624
AG of BRCA2 exon 11GH) previously not detected by
CSGE. Both mutations are located in two large fragments:
453 bp (11a2) and 566 bp (11GH). The reason is that all
fragments must migrate 50 cm from the loading end of the
capillary array to the detection window. The increased
length of migration allows better resolution of closely
migrating bands (16, 25). In standard CSGE, larger frag-
ments may migrate only a short distance (10 cm for
fragments of 500 bp) to retain the shorter fragments for
visualization. In fact, band shifts corresponding to these
two “new” mutations were also observed in standard
CSGE after we increased the electrophoresis run time.
According to the BIC database, 11 of the 48 SNS detected
had been found only by direct sequencing (4 ). Altogether
these results suggest that our method may have an
accuracy similar to that of direct sequencing, regarded as
the gold standard technique for mutation detection, al-
though an additional comparative study should be con-
ducted to corroborate this point.
Several authors have reported that the sensitivities of
HA and single-strand conformation polymorphism anal-
ysis depend on the locations of mutations with respect to
the ends of the PCR fragment (8, 17). It has been sug-
gested that mutations located within 50 bp of the ends of
the PCR product are difficult to detect. We have not found
any effect of a mutation’s position on its detection because
in our sample 6 of 57 DNA changes were of this type
(DNA variants IVS1-115 TC, IVS8-58delT, and 710 CT
from BRCA1 and 1342 CA, 1593 AG, and 10462 AG
from BRCA2).
The different peak patterns of distinct single nucleotide
changes in the same fragment support the specificity of
this technique (Fig. 3A). Therefore, a specific peak pattern
could be assigned automatically to one mutation. Addi-
tionally, homozygous wild-type samples can be differen-
tiated from homozygous mutant samples in some fre-
quent DNA variants (Fig. 3B). However, taking into
account the presence of slightly altered peak patterns (Fig.
2B), sequencing of all anomalous migration patterns is
recommended to differentiate possible false positives.
It is also worth mentioning that the cost per sample of
this technique is low. Other than the purchase price of a
DNA sequencer and the costs related to the common
procedures for both techniques, the total costs per sample
for BRCA1 and BRCA2 analysis by capillary HA are
similar to those of CSGE (in fact, €6, or US $6.90 less in the
case of capillary HA). The relatively high costs of the
ABI3100 consumables (principally the capillary array and
the polymer) are compensated by the minimal consump-
tion of reagents and the long lifespan of the capillary
array. In fact, only 50–80 L of polymer are needed to fill
the 16 capillaries, and at the time this manuscript was
submitted we had conducted more than 150 assays with
the same capillary array. We estimate that the total cost
per sample of our technique is approximately eightfold
lower than that of direct sequencing, as stated by other
authors (26 ). We therefore strongly recommend the use of
capillary HA as a prescreening strategy.
Finally, there are other possible ways to increase the
throughput of the technique. One way is through the use
of robotic systems to set up PCR reactions and post-PCR
procedures, which would greatly reduce operation time.
Another way is through the use of 96-capillary platforms,
which would increase the throughput by sixfold. A third
way is through the introduction of five different labels,
which are currently available (Dye Set G5; Applied Bio-
systems), and a fourth way is through the development of
specific software that automatically identifies putative
abnormal peak patterns. In fact, we are currently collab-
orating with a bioinformatics group for this purpose.
In conclusion, fluorescent HA of BRCA1 and BRCA2 in
multicapillary automated sequencers is fast, easy, inex-
pensive, and sensitive and allows the mutational analysis
of both genes in a short period of time. This method could
be useful for mutational screening of other large and
complex genes, such as NF1 (MIM 162200), APC (MIM
175100), or P53 (MIM 191170), to speed up their test times.
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